Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.

Jason Alexander Roberts David P NicolauIgnacio Martin-LoechesC Andrew DerykeMaria C LosadaJiejun DuMunjal PatelMatthew L RizkAmanda PaschkeLuke F Chen

Published in: JAC-antimicrobial resistance (2023)

Prescribing information-defined dose adjustments in participants with baseline RI and full dosing of imipenem/cilastatin/relebactam 1.25 g every 6 h for participants with normal renal function or augmented renal clearance achieved sufficiently high drug exposures and favourable safety and efficacy profiles.

Keyphrases

adverse drug
primary care
healthcare
air pollution
emergency department
mechanical ventilation
drug induced